SCHEMBL30632943

SCHEMBL30632943

Fc1cc(Br)ccc1C=Cc1ncco1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 4/20 0.33
▸ GPR183 P32249 1/20 0.33
▸ DGAT1 O75907 1/20 0.33
▸ NPC1 O15118 3/20 0.32
▸ RAB9A P51151 3/20 0.32
▸ PIK3R1 P27986 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ NTSR1 P30989 1/20 0.31
▸ ALOX5AP P20292 1/20 0.31
▸ FEN1 P39748 1/20 0.31
▸ GRM4 Q14833 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ SLC22A12 Q96S37 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30632897 0.84 NFE2L2 (0.50) NFE2L2
SCHEMBL30633073 0.82 NPC1 (0.36) NFE2L2GPR183NPC1RAB9APIK3R1
SCHEMBL28473621 0.79 CYP1A1 (0.37) NFE2L2ALOX5APFEN1
SCHEMBL30624911 0.78 CYP1A1 (0.55) NFE2L2NPC1RAB9AMAPK1CYP1A2
SCHEMBL30632963 0.78 NFE2L2 (0.55) NFE2L2NPC1RAB9AGRM4SMN1; SMN2
SCHEMBL30632881 0.76 CBFB (0.39) NPC1RAB9AALOX5APFEN1MAPK1
SCHEMBL30632941 0.76 HTR2A (0.38) —
SCHEMBL30632879 0.76 ALDH1A1 (0.39) NPC1RAB9ANTSR1ALDH1A1MAPT
SCHEMBL30632906 0.75 NUDT1 (0.36) NFE2L2GRM4CYP2C19
SCHEMBL30632981 0.74 RAB9A (0.43) NPC1RAB9AALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111886234-B Heterocyclic mitochondrial activity inhibitors and uses thereof 蒙特利尔大学 2023-12-15 — — CN disclosed
Send feedback